Case of de novo psoriasis possibly triggered by nivolumab

J Dermatol. 2017 Jan;44(1):99-100. doi: 10.1111/1346-8138.13450. Epub 2016 May 14.

Authors

Susumu Murata¹, Sakae Kaneko¹, Yuji Harada², Noriaki Aoi³, Eishin Morita¹

Affiliations

¹ Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan.
² Department of Surgical Pathology, Shimane University Faculty of Medicine, Izumo, Japan.
³ Department of Otorhinolaryngology, Shimane University Faculty of Medicine, Izumo, Japan.

PMID: 27177467
DOI: 10.1111/1346-8138.13450

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Cutaneous
Aged, 80 and over
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Betamethasone / administration & dosage
Betamethasone / analogs & derivatives
Betamethasone / therapeutic use
Calcitriol / administration & dosage
Calcitriol / analogs & derivatives
Calcitriol / therapeutic use
Drug Combinations
Humans
Male
Melanoma / drug therapy*
Melanoma / pathology
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Staging
Nivolumab
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / metabolism
Psoriasis / chemically induced*
Psoriasis / diagnosis
Psoriasis / immunology
Psoriasis / pathology
Signal Transduction / immunology
Th1 Cells / immunology
Th17 Cells / immunology

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Drug Combinations
Programmed Cell Death 1 Receptor
betamethasone dipropionate, calcipotriol drug combination
Nivolumab
Betamethasone
Calcitriol